Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The Synergy BPC-157 focuses on the local injury environment
The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States
See where to inject KLOW peptide for the full anatomical breakdown
Always seek medical advice if you notice unusual bruising or bleeding
Contact your GP, trial coordinator, or a healthcare professional promptly but without the urgency of 999 if you experience: A widespread or rapidly spreading rash, particularly if accompanied by fever, joint pain, or malaise Blistering, peeling, or open sores on the skin, which may indicate a more serious dermatological reaction Persistent or worsening injection site reactions that do not resolve within a few days Skin changes accompanied by systemic symptoms such as fatigue, fever, or lymph node swelling Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome or toxic epidermal necrolysis, are rare but serious drug-related skin conditions requiring emergency assessment
This is exactly why Med Matrix runs an 80+ biomarker lab panel rather than just prescribing the medication
